Spondyloarthritis & psoriatic arthritis
Association of nociplastic and neuropathic pain components with the presence of residual symptoms in patients with axial spondyloarthritis receiving biological disease-modifying antirheumatic drugs
An erratum to this article was published (RMD Open, 4 Apr 2024 ↗)
Authors' conclusion
Both NoP and NP components seem to be associated with residual symptoms in patients with r-axSpA receiving treatment with bDMARDs.
Study context
- Population
- Patients with radiographic axial spondyloarthritis (r-axSpA) from the GErman SPondyloarthritis Inception Cohort receiving a bDMARD for at least 3 months
- Participants
- 78 patients
- Outcome
- Association of nociplastic (NoP) (WPI) and neuropathic pain (NP) (PainDETECT) components with residual symptoms (ASDAS, BASDAI)
Methodological detailsunivariable and multivariable regression, cluster analysis
- Univariable and multivariable regression
- Cluster analysis
Main finding
As reported in the abstract
Widespread Pain Index (WPI) with Axial Spondyloarthritis Disease Activity Score (ASDAS), b
0.1 (0.04 to 0.17) (95% CI)
PainDETECT (PD) with ASDAS, b
0.05 (0.02 to 0.08) (95% CI)
WPI with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), b
0.24 (0.08 to 0.39) (95% CI)
PD with BASDAI, b
0.17 (0.1 to 0.25) (95% CI)
Observational data: associations, not effects.
Further findings
Relevant residual symptoms (BASDAI ≥4)
- WPI, OR
- 1.93 (1.09 to 4.15) (95% CI)
- PD, OR
- 1.32 (1.04 to 1.85) (95% CI)
Patients with normal C reactive protein (CRP)
- The effects were present also in patients with normal level of CRP
Cluster analysis
- Distinct pain distribution profiles
- 3
- Specific sensory symptom constellations
- 4
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →